PARP Inhibitors Promising Beyond BRCA1/2 Altered Tumors

This article originally appeared here.
Share this content:
PARP Inhibitors Promising Beyond <i>BRCA1/2</i> Altered Tumors
PARP Inhibitors Promising Beyond BRCA1/2 Altered Tumors

THURSDAY, Nov. 2, 2017 (HealthDay News) -- PARP inhibitors demonstrate activity in triple-negative breast cancer (TNBC) tumors without BRCA1/2 mutations, according to a study published online Nov. 1 in Clinical Cancer Research.

Kurt W. Evans, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues generated 26 breast cancer patient-derived xenografts (PDXs) from surgical samples of primary or locally recurrent tumors from 25 patients. The authors determined the efficacy of a panel of standard and investigational agents to perform phenotypic profiling.

The researchers found that 24 of the PDXs were from TNBC and that they harbored a heterogeneous set of genomic alterations, representing all TNBC molecular subtypes. PDXs varied in the extent of PI3K and MAPK activation on reverse-phase protein arrays. They also varied in their sensitivity to chemotherapeutic agents. Growth was repressed by PI3K, mTOR, and MEK inhibitors, but these did not cause tumor regression. In five of 12 PDXs, the PARP inhibitor talazoparib caused dramatic regression. Four of five talazoparib-sensitive models did not harbor germline BRCA1/2 mutations; several had somatic alterations in homologous repair pathways, including deletion of ATM and alterations in BRCA2.

"Here we show that PARP inhibition can have activity beyond germline BRCA1/2 altered tumors, causing regression in a variety of molecular subtypes," the authors write. "These models represent an opportunity for the discovery of rational combinations with targeted therapies and predictive biomarkers."

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

High Costs Associated With Physician Burnout, Attrition

High Costs Associated With Physician Burnout, Attrition

Economic loss at Stanford over two years expected to range from $15.5 million to $55.5 million

Insulin Doesn't Prevent Diabetes in Relatives of T1DM Patients

Insulin Doesn't Prevent Diabetes in Relatives of T1DM ...

Oral insulin doesn't delay onset in autoantibody-positive relatives of patients with type 1 diabetes

Workplace Sexual Harassment Ongoing in Women, Up for Men

Workplace Sexual Harassment Ongoing in Women, Up for ...

Women report more adverse effects after SH than men, but SH can trigger depression, anxiety in men

is free, fast, and customized just for you!

Already a member?

Sign In Now »